Abbott Laboratories (NYSE: ABT) Stock Competitors & Peer Comparison
See ABT's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ABT and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABT | $108.62 | +0.75% | 188B | 20.86 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $345.81 | +2.00% | 132.5B | 25.82 | $13.39 | +1.01% |
| MDT | $89.41 | +2.58% | 114.4B | 16.17 | $5.53 | +3.20% |
| BSX | $50.46 | +2.33% | 75B | 16.28 | $3.10 | N/A |
| EW | $92.03 | +2.57% | 53B | 34.09 | $2.70 | N/A |
| DXCM | $87.65 | +3.42% | 33.1B | 37.62 | $2.33 | N/A |
| RMD | $220.05 | +3.83% | 31.9B | 20.44 | $10.77 | +1.09% |
| PHG | $26.94 | +0.79% | 26.3B | 15.39 | $1.75 | +3.68% |
| ZBH | $97.78 | +1.27% | 18.9B | 11.53 | $8.48 | +0.99% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
ABT vs BSX-PA Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABT's ROE is +0.11%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
ABT vs SYK Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SYK has a market cap of 132.5B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SYK trades at $345.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SYK's P/E ratio is 25.82. In terms of profitability, ABT's ROE is +0.11%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ABT is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SYK's competition here
Medtronic plc (NYSE: MDT)
ABT vs MDT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, MDT has a market cap of 114.4B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while MDT trades at $89.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas MDT's P/E ratio is 16.17. In terms of profitability, ABT's ROE is +0.11%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
ABT vs BSX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BSX has a market cap of 75B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BSX trades at $50.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BSX's P/E ratio is 16.28. In terms of profitability, ABT's ROE is +0.11%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ABT vs EW Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, EW has a market cap of 53B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while EW trades at $92.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas EW's P/E ratio is 34.09. In terms of profitability, ABT's ROE is +0.11%, compared to EW's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for ABT.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ABT vs DXCM Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, DXCM has a market cap of 33.1B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while DXCM trades at $87.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas DXCM's P/E ratio is 37.62. In terms of profitability, ABT's ROE is +0.11%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ABT is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
ABT vs RMD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, RMD has a market cap of 31.9B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while RMD trades at $220.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas RMD's P/E ratio is 20.44. In terms of profitability, ABT's ROE is +0.11%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ABT is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ABT vs PHG Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, PHG has a market cap of 26.3B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while PHG trades at $26.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas PHG's P/E ratio is 15.39. In terms of profitability, ABT's ROE is +0.11%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ABT.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ABT vs ZBH Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ZBH has a market cap of 18.9B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ZBH trades at $97.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ZBH's P/E ratio is 11.53. In terms of profitability, ABT's ROE is +0.11%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ABT vs ABMD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ABT's ROE is +0.11%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
ABT vs PEN Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while PEN trades at $325.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas PEN's P/E ratio is 85.11. In terms of profitability, ABT's ROE is +0.11%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ABT is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ABT.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
ABT vs SNN Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SNN trades at $30.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SNN's P/E ratio is 14.16. In terms of profitability, ABT's ROE is +0.11%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ABT is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SNN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ABT vs SWAV Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABT's ROE is +0.11%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ABT is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ABT vs ALGN Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ALGN trades at $176.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ALGN's P/E ratio is 15.83. In terms of profitability, ABT's ROE is +0.11%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, ABT is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
ABT vs GMED Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while GMED trades at $86.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas GMED's P/E ratio is 19.40. In terms of profitability, ABT's ROE is +0.11%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for ABT.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
ABT vs GKOS Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, GKOS has a market cap of 10.7B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while GKOS trades at $181.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas GKOS's P/E ratio is -210.81. In terms of profitability, ABT's ROE is +0.11%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ABT is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
ABT vs PODD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while PODD trades at $142.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas PODD's P/E ratio is 24.34. In terms of profitability, ABT's ROE is +0.11%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ABT is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ABT vs BIO Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BIO has a market cap of 9.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BIO trades at $354.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BIO's P/E ratio is 38.24. In terms of profitability, ABT's ROE is +0.11%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ABT is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ABT vs BIO-B Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BIO-B trades at $349.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BIO-B's P/E ratio is 103.54. In terms of profitability, ABT's ROE is +0.11%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ABT is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ABT.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
ABT vs MASI Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas MASI's P/E ratio is 44.43. In terms of profitability, ABT's ROE is +0.11%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ABT is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ABT.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
ABT vs BRKR Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BRKR has a market cap of 8.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BRKR trades at $56.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BRKR's P/E ratio is 28.30. In terms of profitability, ABT's ROE is +0.11%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ABT vs NARI Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABT's ROE is +0.11%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ABT is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ABT.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
ABT vs ITGR Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ITGR trades at $125.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ITGR's P/E ratio is 19.70. In terms of profitability, ABT's ROE is +0.11%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ABT is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
ABT vs LIVN Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while LIVN trades at $76.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas LIVN's P/E ratio is 18.17. In terms of profitability, ABT's ROE is +0.11%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ABT vs IRTC Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while IRTC trades at $124.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas IRTC's P/E ratio is -194.97. In terms of profitability, ABT's ROE is +0.11%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ABT is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IRTC's competition here
Haemonetics Corporation (NYSE: HAE)
ABT vs HAE Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, HAE has a market cap of 3.9B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while HAE trades at $86.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas HAE's P/E ratio is 17.29. In terms of profitability, ABT's ROE is +0.11%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ABT.Check HAE's competition here
Axonics, Inc. (NASDAQ: AXNX)
ABT vs AXNX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ABT's ROE is +0.11%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ABT is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ABT.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ABT vs TMDX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while TMDX trades at $88.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas TMDX's P/E ratio is 44.88. In terms of profitability, ABT's ROE is +0.11%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ABT is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ABT vs AXGN Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while AXGN trades at $48.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas AXGN's P/E ratio is 126.89. In terms of profitability, ABT's ROE is +0.11%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ABT is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ABT vs BFLY Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BFLY has a market cap of 2.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BFLY trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BFLY's P/E ratio is -40.42. In terms of profitability, ABT's ROE is +0.11%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ABT is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ABT vs UFPT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while UFPT trades at $325.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas UFPT's P/E ratio is 33.20. In terms of profitability, ABT's ROE is +0.11%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ABT is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ABT vs ESTA Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ESTA trades at $75.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ESTA's P/E ratio is -59.57. In terms of profitability, ABT's ROE is +0.11%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ABT is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ABT vs NUVA Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABT's ROE is +0.11%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
ABT vs NVCR Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while NVCR trades at $17.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas NVCR's P/E ratio is -11.31. In terms of profitability, ABT's ROE is +0.11%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ABT is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ABT vs INSP Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while INSP trades at $59.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas INSP's P/E ratio is 26.31. In terms of profitability, ABT's ROE is +0.11%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ABT is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ABT.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ABT vs TNDM Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while TNDM trades at $22.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas TNDM's P/E ratio is -20.74. In terms of profitability, ABT's ROE is +0.11%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ABT is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
ABT vs CNMD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CNMD trades at $49.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CNMD's P/E ratio is 10.87. In terms of profitability, ABT's ROE is +0.11%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ABT vs ATEC Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ATEC trades at $9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ATEC's P/E ratio is -155.17. In terms of profitability, ABT's ROE is +0.11%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ABT is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ATEC's competition here
Enovis Corporation (NYSE: ENOV)
ABT vs ENOV Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ENOV trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ENOV's P/E ratio is 6.96. In terms of profitability, ABT's ROE is +0.11%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ABT is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ABT vs IART Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while IART trades at $17.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas IART's P/E ratio is 7.23. In terms of profitability, ABT's ROE is +0.11%, compared to IART's ROE of -0.01%. Regarding short-term risk, ABT is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
ABT vs AORT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while AORT trades at $26.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas AORT's P/E ratio is 45.28. In terms of profitability, ABT's ROE is +0.11%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ABT is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
ABT vs HSKA Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABT's ROE is +0.11%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABT is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ABT.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ABT vs PRCT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while PRCT trades at $21.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas PRCT's P/E ratio is -11.19. In terms of profitability, ABT's ROE is +0.11%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ABT is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ABT vs AVNS Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ABT's ROE is +0.11%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ABT is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ABT.Check AVNS's competition here
IRadimed Corporation (NASDAQ: IRMD)
ABT vs IRMD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while IRMD trades at $90.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas IRMD's P/E ratio is 45.36. In terms of profitability, ABT's ROE is +0.11%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ABT is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IRMD's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ABT vs LMRI Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while LMRI trades at $11.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas LMRI's P/E ratio is -22.84. In terms of profitability, ABT's ROE is +0.11%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ABT is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ABT vs SILK Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABT's ROE is +0.11%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ABT is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
ABT vs FNA Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABT's ROE is +0.11%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ABT is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ABT.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
ABT vs BVS Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BVS has a market cap of 945.8M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BVS trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BVS's P/E ratio is 18.37. In terms of profitability, ABT's ROE is +0.11%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ABT is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
ABT vs INMD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, INMD has a market cap of 873.1M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while INMD trades at $15.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas INMD's P/E ratio is 10.55. In terms of profitability, ABT's ROE is +0.11%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ABT is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ABT.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ABT vs AVR Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, AVR has a market cap of 866.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while AVR trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas AVR's P/E ratio is -4.00. In terms of profitability, ABT's ROE is +0.11%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ABT is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ABT vs CSII Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABT's ROE is +0.11%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABT is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ABT.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ABT vs SIBN Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SIBN has a market cap of 835.5M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SIBN trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SIBN's P/E ratio is -55.41. In terms of profitability, ABT's ROE is +0.11%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ABT is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SIBN's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ABT vs VREX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while VREX trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas VREX's P/E ratio is 19.43. In terms of profitability, ABT's ROE is +0.11%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ABT is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ABT.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ABT vs SSII Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SSII has a market cap of 746.5M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SSII trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SSII's P/E ratio is -72.75. In terms of profitability, ABT's ROE is +0.11%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ABT is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SSII's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ABT vs BBNX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BBNX has a market cap of 737.8M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BBNX trades at $16.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BBNX's P/E ratio is -10.86. In terms of profitability, ABT's ROE is +0.11%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ABT is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BBNX's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ABT vs CBLL Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CBLL has a market cap of 732.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CBLL trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CBLL's P/E ratio is -11.84. In terms of profitability, ABT's ROE is +0.11%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ABT is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ABT vs AHCO Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, AHCO has a market cap of 710.2M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while AHCO trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas AHCO's P/E ratio is 10.65. In terms of profitability, ABT's ROE is +0.11%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ABT is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AHCO's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ABT vs TCMD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, TCMD has a market cap of 657.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while TCMD trades at $29.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas TCMD's P/E ratio is 33.11. In terms of profitability, ABT's ROE is +0.11%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TCMD's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ABT vs SRDX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ABT's ROE is +0.11%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ABT is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ABT vs CTKB Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CTKB has a market cap of 601.8M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CTKB trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CTKB's P/E ratio is -24.69. In terms of profitability, ABT's ROE is +0.11%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ABT is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CTKB's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
ABT vs BWAY Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BWAY has a market cap of 600.9M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BWAY trades at $15.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BWAY's P/E ratio is 38.92. In terms of profitability, ABT's ROE is +0.11%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ABT is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for ABT.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ABT vs KIDS Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, KIDS has a market cap of 597.9M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while KIDS trades at $23.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas KIDS's P/E ratio is -19.73. In terms of profitability, ABT's ROE is +0.11%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ABT is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ABT vs APEN Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABT's ROE is +0.11%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ABT.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ABT vs DCTH Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, DCTH has a market cap of 575.5M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while DCTH trades at $16.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas DCTH's P/E ratio is 1667.00. In terms of profitability, ABT's ROE is +0.11%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ABT is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ABT.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ABT vs ZIMV Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ABT's ROE is +0.11%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ABT is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
ABT vs CERS Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CERS has a market cap of 507.8M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CERS trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CERS's P/E ratio is -50.30. In terms of profitability, ABT's ROE is +0.11%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ABT is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ABT vs NPCE Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, NPCE has a market cap of 507.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while NPCE trades at $14.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas NPCE's P/E ratio is -25.66. In terms of profitability, ABT's ROE is +0.11%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ABT is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ABT vs CLPT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CLPT has a market cap of 436.9M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CLPT trades at $14.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CLPT's P/E ratio is -12.35. In terms of profitability, ABT's ROE is +0.11%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ABT is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ABT vs SGHT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SGHT has a market cap of 419M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SGHT trades at $7.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SGHT's P/E ratio is -13.75. In terms of profitability, ABT's ROE is +0.11%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ABT vs OFIX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, OFIX has a market cap of 414.7M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while OFIX trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas OFIX's P/E ratio is -13.40. In terms of profitability, ABT's ROE is +0.11%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ABT is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check OFIX's competition here
Picard Medical, Inc. (AMEX: PMI)
ABT vs PMI Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, PMI has a market cap of 375.9M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while PMI trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas PMI's P/E ratio is -3.05. In terms of profitability, ABT's ROE is +0.11%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ABT is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PMI's competition here
Carlsmed, Inc. (NASDAQ: CARL)
ABT vs CARL Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CARL has a market cap of 373.2M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CARL trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CARL's P/E ratio is -9.60. In terms of profitability, ABT's ROE is +0.11%, compared to CARL's ROE of -0.38%. Regarding short-term risk, ABT is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ABT vs PACB Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while PACB trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas PACB's P/E ratio is -2.80. In terms of profitability, ABT's ROE is +0.11%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ABT is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PACB's competition here
Electromed, Inc. (AMEX: ELMD)
ABT vs ELMD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ELMD has a market cap of 353.1M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ELMD trades at $42.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ELMD's P/E ratio is 36.44. In terms of profitability, ABT's ROE is +0.11%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ABT is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ELMD's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ABT vs CATX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CATX has a market cap of 342.1M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CATX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CATX's P/E ratio is -2.13. In terms of profitability, ABT's ROE is +0.11%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ABT is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CATX's competition here
CapsoVision, Inc. (NASDAQ: CV)
ABT vs CV Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, CV has a market cap of 333.8M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while CV trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas CV's P/E ratio is -2.67. In terms of profitability, ABT's ROE is +0.11%, compared to CV's ROE of +1.27%. Regarding short-term risk, ABT is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ABT vs SENS Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SENS has a market cap of 315.1M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SENS trades at $7.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SENS's P/E ratio is -3.77. In terms of profitability, ABT's ROE is +0.11%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ABT is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SENS's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ABT vs SMLR Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ABT's ROE is +0.11%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ABT is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ABT vs TMCI Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, TMCI has a market cap of 303M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while TMCI trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas TMCI's P/E ratio is -4.97. In terms of profitability, ABT's ROE is +0.11%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ABT is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TMCI's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
ABT vs ANIK Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ANIK has a market cap of 286.7M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ANIK trades at $20.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ANIK's P/E ratio is 43.71. In terms of profitability, ABT's ROE is +0.11%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ANIK's competition here
RxSight, Inc. (NASDAQ: RXST)
ABT vs RXST Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, RXST has a market cap of 272M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while RXST trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas RXST's P/E ratio is -7.06. In terms of profitability, ABT's ROE is +0.11%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ABT.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
ABT vs PROF Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, PROF has a market cap of 266.7M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while PROF trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas PROF's P/E ratio is -5.92. In terms of profitability, ABT's ROE is +0.11%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ABT is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PROF's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ABT vs MGRM Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ABT's ROE is +0.11%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ABT.Check MGRM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ABT vs FOCL Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, FOCL has a market cap of 227.9M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while FOCL trades at $6.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas FOCL's P/E ratio is -7.82. In terms of profitability, ABT's ROE is +0.11%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, ABT is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check FOCL's competition here
Nevro Corp. (NYSE: NVRO)
ABT vs NVRO Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABT's ROE is +0.11%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABT is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ABT.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ABT vs TLSI Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, TLSI has a market cap of 211.5M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while TLSI trades at $5.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas TLSI's P/E ratio is -3.32. In terms of profitability, ABT's ROE is +0.11%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ABT is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TLSI's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ABT vs BSGM Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ABT's ROE is +0.11%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ABT is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSGM's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ABT vs RCEL Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, RCEL has a market cap of 188.8M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while RCEL trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas RCEL's P/E ratio is -4.84. In terms of profitability, ABT's ROE is +0.11%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ABT is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check RCEL's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ABT vs MDGS Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ABT's ROE is +0.11%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
ABT vs INGN Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, INGN has a market cap of 163M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while INGN trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas INGN's P/E ratio is -6.62. In terms of profitability, ABT's ROE is +0.11%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ABT is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ABT vs QIPT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ABT's ROE is +0.11%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ABT is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ABT.Check QIPT's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ABT vs STIM Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, STIM has a market cap of 151M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while STIM trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas STIM's P/E ratio is -4.02. In terms of profitability, ABT's ROE is +0.11%, compared to STIM's ROE of -1.65%. Regarding short-term risk, ABT is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check STIM's competition here
Quanterix Corporation (NASDAQ: QTRX)
ABT vs QTRX Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, QTRX has a market cap of 114M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while QTRX trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas QTRX's P/E ratio is -1.51. In terms of profitability, ABT's ROE is +0.11%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ABT is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
ABT vs ICAD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ABT's ROE is +0.11%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ABT is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ICAD's competition here
Solana Company (NASDAQ: HSDT)
ABT vs HSDT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, HSDT has a market cap of 99.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while HSDT trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas HSDT's P/E ratio is -0.02. In terms of profitability, ABT's ROE is +0.11%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, ABT is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check HSDT's competition here
Owlet, Inc. (NYSE: OWLT)
ABT vs OWLT Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, OWLT has a market cap of 98.4M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while OWLT trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas OWLT's P/E ratio is -38.86. In terms of profitability, ABT's ROE is +0.11%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, ABT is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check OWLT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ABT vs LUCD Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, LUCD has a market cap of 98.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas LUCD's P/E ratio is -2.60. In terms of profitability, ABT's ROE is +0.11%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, ABT is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LUCD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ABT vs HJLI Comparison August 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 188B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ABT is priced at $108.62 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 20.86, whereas HJLI's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.11%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ABT is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check HJLI's competition here